Trial Profile
A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- 03 May 2023 Status changed from active, no longer recruiting to completed.
- 17 Mar 2023 Planned End Date changed from 30 Dec 2022 to 30 Dec 2024.
- 17 Mar 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2024.